Prelude
Laguna Hills, California, United States · Biotechnology, Biotechnology Research, Health Care · 35 employees
PreludeDx is a precision diagnostics company dedicated to providing actionable tools for managing early-stage breast cancer. Its first test, DCISionRT, is the result of over a decade of research focused on DCIS and was developed using technology licensed from the University of California, San Francisco. Designed to address the critical question faced by DCIS patients — What is my risk of recurrenc
Funding history
- Series series a — $20.0M — May 2026
- Funding Round — $5.0M — Nov 2025
- Series seed — $7.6M — Nov 2024
- Funding Round — $24.0M — Apr 2022
- Funding Round — $9.3M — Feb 2022
Recent signals
- May 20, 2026: Raised $20.0M in Series series a
- Jan 22, 2026: Prelude Corporation Appoints MiMi Reyes as Senior Vice President of Operations
- Nov 06, 2025: Raised $5.0M
- Nov 13, 2024: Raised $7.6M in Series seed
- May 02, 2024: Prelude Corporation Appoints Dr. Pat Whitworth as Chief Medical Officer
- Feb 08, 2024: PreludeDx Appoints Chris Emery, VP of Strategic Marketing and Business Development
- Apr 12, 2022: Raised $24.0M
- Feb 15, 2022: Raised $9.3M
See plans & pricing → Track Prelude’s funding, hiring, and signals — with verified contacts — on Fundz.